Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Acinetobacter baumannii, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia with Vitek 2 (2009 FDA) and CLSI M100S 26th Edition Breakpoints
- 1 February 2017
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 55 (2) , 450-456
Abstract
The performances of Vitek 2 AST-GN69 and AST-XN06 cards were compared to Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution (BMD) for 99 isolates of Pseudomonas aeruginosa , 26 Acinetobacter baumannii isolates, and 11 Stenotrophomonas maltophilia isolates. In total, 15 antimicrobials were evaluated, with 11 for P. aeruginosa , 14 for A. baumannii , and 2 for S. maltophilia . Categorical agreement (CA) was assessed using both Vitek 2 breakpoints and 2016 CLSI M100S 26th edition breakpoints. The essential agreement values for P. aeruginosa , A. baumannii , and S. maltophilia were 99.5%, 99.2%, and 100%, respectively. The CA values for P. aeruginosa , A. baumannii , and S. maltophilia were 94.1%, 92.7%, and 95.5%, respectively, by the Vitek 2 breakpoints, and 93.4%, 92.3%, and 95.5%, respectively, by the CLSI breakpoints. Overall, the Vitek 2 performance was comparable to that of BMD using both Vitek 2 breakpoints and 2016 CLSI M100S 26th edition breakpoints. Improved performance was noted for the reformulated piperacillin-tazobactam and imipenem found on the AST-GN69 card, with no very major or major errors noted when using the CLSI breakpoints.Keywords
This publication has 11 references indexed in Scilit:
- Emerging Resistance, New Antimicrobial Agents … but No Tests! The Challenge of Antimicrobial Susceptibility Testing in the Current US Regulatory LandscapeClinical Infectious Diseases, 2016
- Vital Signs: Preventing Antibiotic-Resistant Infections in Hospitals — United States, 2014MMWR. Morbidity and Mortality Weekly Report, 2016
- Performance of Vitek 2 for Antimicrobial Susceptibility Testing of Enterobacteriaceae with Vitek 2 (2009 FDA) and 2014 CLSI BreakpointsJournal of Clinical Microbiology, 2015
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClinical Microbiology and Infection, 2012
- Carbapenem Susceptibility Testing Errors Using Three Automated Systems, Disk Diffusion, Etest, and Broth Microdilution and Carbapenem Resistance Genes in Isolates of Acinetobacter baumannii-calcoaceticus ComplexAntimicrobial Agents and Chemotherapy, 2011
- Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic-Resistant Gram-Negative BacteriaAntimicrobial Agents and Chemotherapy, 2010
- Validation of Vitek 2 Nonfermenting Gram-Negative Cards and Vitek 2 Version 4.02 Software for Identification and Antimicrobial Susceptibility Testing of Nonfermenting Gram-Negative Rods from Patients with Cystic FibrosisJournal of Clinical Microbiology, 2009
- Comparison of different methods of determining β-lactam susceptibility in clinical strains of Pseudomonas aeruginosaJournal of Medical Microbiology, 2009
- Performance of Vitek 2 in Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa Isolates with Different Mechanisms of β-Lactam ResistanceJournal of Clinical Microbiology, 2008
- Accuracies of β-Lactam Susceptibility Test Results for Pseudomonas aeruginosa with Four Automated Systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2)Journal of Clinical Microbiology, 2007